Key result
Lck silencing or inhibition with PP2 enhanced cholesterol efflux and decreased cellular cholesterol content in T cells, indicating Lck inhibits HSP65-mediated reverse cholesterol transport.
Why the study?
Does Lck inhibition improve reverse cholesterol transport in T cells?
Does Lck inhibition improve reverse cholesterol transport in T cells?
Lck is a key molecule in the TCR signaling cascade that inhibits cholesterol efflux, demonstrating a previously unrecognized role of the immune response in reverse cholesterol transport.
Answers are grounded in this paper and cite their sources.
Lck inhibition warrants no clinical consideration yet; leaves open whether TCR signaling modulates human reverse cholesterol transport.
Previously, we reported that heat shock protein (HSP)65 impairs the effects of high-density lipoprotein on macrophages. We also showed that immune response activation adversely affects reverse cholesterol transport (RCT). In this study, we investigated the effects of the Src family kinase lymphocyte-specific protein tyrosine kinase (Lck) and elucidated the mechanism underlying HSP65-regulated cholesterol efflux in T cells. We evaluated cell proliferation, Lck expression, and inflammatory cytokine production in Jurkat cells and CD4+ T cells. HSP65-mediated inhibition of RCT was assessed by evaluating ABCA1, ABCG1, SR-BI, PPAR-γ, and liver X receptor-α expression. A dose-dependent relationship was found between the levels of these proteins and the suppression of cholesterol efflux. Stimulation of Lck-silenced T cells with ionomycin resulted in a decrease in intracellular calcium levels. Treatment of Jurkat cells with PP2, an inhibitor of Src family kinase, inhibited calcium-induced, but not PMA-induced, ERK phosphorylation. NF-κB activation in response to PMA was minimally inhibited in cells stimulated with PP2. HSP65 failed to trigger downstream ERK or JNK phosphorylation or to activate NF-κB or protein kinase C-γ in Lck-silenced cells. Additionally, elevation of intracellular calcium was also impaired. However, HSP65 significantly enhanced cholesterol efflux and decreased cellular cholesterol content by inducing the expression of cholesterol transport proteins in Lck-silenced cells. The treatment of Jurkat cells with PP2 also inhibited cell proliferation and promoted RCT. In conclusion, Lck is a key molecule in the TCR signaling cascade that inhibits cholesterol efflux and upregulates intracellular cholesterol ester content in T cells. Our results demonstrate that the immune response plays a previously unrecognized role in RCT.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2016) studied Reverse cholesterol transport in T cells. Lck silencing and PP2 treatment vs. Control was evaluated on Cholesterol efflux and intracellular cholesterol content. Lck silencing or inhibition with PP2 enhanced cholesterol efflux and decreased cellular cholesterol content in T cells, indicating Lck inhibits HSP65-mediated reverse cholesterol transport.
Synapse has enriched 10 related papers. Consider them for comparative context: